G Gründer1, M Bauer2, M Deuschle3, M Hautzinger4, M Friede5, M J Müller6. 1. Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik RWTH Aachen, Aachen, Deutschland. 2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland. 3. Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie, Universität Heidelberg, Medizinische Fakultät Mannheim, Mannheim, Deutschland. 4. Institut für Klinische Psychologie und Psychotherapie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland. 5. Medical Department, Lundbeck GmbH, Ericusspitze 2, 20457, Hamburg, Deutschland. lumf@lundbeck.com. 6. Klinik für Psychiatrie und Psychotherapie Gießen und Marburg, Vitos Klinikum Gießen-Marburg, Marburg, Deutschland.
Abstract
BACKGROUND: In the context of new drug benefit assessments a list of outcome parameter are evaluated. Currently it is unclear, how different outcome parameters are weighed in the overall assessment. OBJECTIVES: The objective of the survey is to rank relevant outcome parameters in the treatment of depression, which may be considered in benefit the assessment of new antidepressants. MATERIALS AND METHODS: In 2015 a Delphi panel survey with 30 general practitioners and specialists in Germany was performed regarding the benefit assessment of antidepressants. On the basis of two fictive casuistics (patients with depressive disorders) the physicians weighed a range of relevant outcome parameters regarding efficacy, quality of life, safety and tolerability according to their relevance to clinical practice. RESULTS: Regarding efficacy, response, remission and recovery were rated as the most important outcomes. Regarding quality of life, handling of the daily household activities and mental performance were rated as most important. Suicidality was rated as the most important outcome regarding safety and tolerability. CONCLUSIONS: Individual outcome parameters were rated differently by the physicians regarding their relevance to clinical practice. The results indicate that outcome parameters should be weighed differently when assessing the overall benefit of new antidepressants.
BACKGROUND: In the context of new drug benefit assessments a list of outcome parameter are evaluated. Currently it is unclear, how different outcome parameters are weighed in the overall assessment. OBJECTIVES: The objective of the survey is to rank relevant outcome parameters in the treatment of depression, which may be considered in benefit the assessment of new antidepressants. MATERIALS AND METHODS: In 2015 a Delphi panel survey with 30 general practitioners and specialists in Germany was performed regarding the benefit assessment of antidepressants. On the basis of two fictive casuistics (patients with depressive disorders) the physicians weighed a range of relevant outcome parameters regarding efficacy, quality of life, safety and tolerability according to their relevance to clinical practice. RESULTS: Regarding efficacy, response, remission and recovery were rated as the most important outcomes. Regarding quality of life, handling of the daily household activities and mental performance were rated as most important. Suicidality was rated as the most important outcome regarding safety and tolerability. CONCLUSIONS: Individual outcome parameters were rated differently by the physicians regarding their relevance to clinical practice. The results indicate that outcome parameters should be weighed differently when assessing the overall benefit of new antidepressants.
Authors: Marion Danner; J Marjan Hummel; Fabian Volz; Jeannette G van Manen; Beate Wiegard; Charalabos-Markos Dintsios; Hilda Bastian; Andreas Gerber; Maarten J Ijzerman Journal: Int J Technol Assess Health Care Date: 2011-10 Impact factor: 2.188
Authors: Syed Shabab Wahid; Katherine Ottman; Raya Hudhud; Kamal Gautam; Helen L Fisher; Christian Kieling; Valeria Mondelli; Brandon A Kohrt Journal: J Affect Disord Date: 2020-10-01 Impact factor: 4.839
Authors: Syed Shabab Wahid; Gloria A Pedersen; Katherine Ottman; Abigail Burgess; Kamal Gautam; Thais Martini; Anna Viduani; Olufisayo Momodu; Crystal Lam; Helen L Fisher; Christian Kieling; Abiodun O Adewuya; Valeria Mondelli; Brandon A Kohrt Journal: BMJ Open Date: 2020-07-28 Impact factor: 2.692